AMENDMENTS

IN THE CLAIMS

Cancel claim 57 without prejudice to renewal.

Please enter the amendments to claims 58-61, 63, 64, 66, 67, 69, and 70.

Please add new claim 72.

1 - 57. (Canceled)

58. (Currently Amended) The method of claim 72 ~~57~~, wherein the aerosol particle size is adjusted such that the aerodynamic diameter of the aerosol particles is in a range of from 1-3 μm and alveoli of the patient's respiratory tract are targeted.

59. (Currently Amended) The method of claim 72 ~~57~~, wherein the aerosol particle size is adjusted such that the aerodynamic diameter of the aerosol particles is in a range of from 4-6 μm and central airways of the patient's respiratory tract are targeted.

60. (Currently Amended) The method of claim 72 ~~57~~, wherein the aerosol particle size is adjusted such that the aerodynamic diameter of the aerosol particles is in a range of from 7-10 μm and upper airways of the patient's respiratory tract are targeted.

61. (Currently Amended) The method as claimed in claim 72 ~~57~~, wherein the aerosol particles are further comprised of a cationic lipid.

62. (Previously Presented) The method as claimed in claim 61, wherein the cationic lipid is selected from the group consisting of DOTMA, DOTAP and DC-Chol.

63. (Currently Amended) The method as claimed in claim 72 ~~57~~, wherein the condensing agent is selected from the group consisting of protamine sulfate, polylysine , and combinations thereof.

64. (Currently Amended) The method as claimed in claim 72 ~~57~~, wherein the condensing agent is protamine sulfate.

65. (Canceled)

66. (Currently Amended) The method as claimed in claim 72 ~~57~~, wherein the condensing agent is a polycation.

67. (Currently Amended) The method as claimed in 72 ~~57~~, wherein the condensing agent is a polyamine.

68. (Previously Presented) The method as claimed in claim 67, wherein the polyamine is selected from the group consisting of spermine, spermidine and putrescine.

69. (Currently Amended) The method as claimed in claim 72 ~~57~~, wherein the condensing agent is selected from the group consisting of poly-lysine and poly-ethyleneimine.

70. (Currently Amended) The method of claim 72 ~~57~~, further comprising:

adjusting the patient's inspiratory flow rate inside a range of about 0.10 to about 4.0 liters/second.

71. (Previously Presented) The method of claim 70, wherein the flow rate is adjusted inside a range of about 0.2 to about 3.0 liters per second.

72. (New) A method of targeting an area of a patient's respiratory tract, comprising:

aerosolizing a formulation to create aerosol particles comprised of polynucleotides and a polynucleotide condensing agent wherein condensed polynucleotides in the aerosolized particles have a size of from about 20 to about 50 nanometers;

adjusting an aerodynamic diameter of the aerosolized particles based on a targeted area of a patient's respiratory tract;

controlling the patient's inhaled volume of aerosolized formulation and aerosol-free air.